A Phase 3 trial presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in 2024 showed that tolebrutinib, a new investigational drug, was effective in delaying disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The trial demonstrated that tolebrutinib slowed the onset of 6-month confirmed disability progression by 31% compared to placebo. While the drug showed promise in improving disability, it also raised concerns about liver toxicity. Despite potential safety issues, researchers believe that tolebrutinib could be a valuable treatment option for patients with progressive MS who have not responded to current therapies.
Source link
Novel Agent First to Slow Disability in nrSPMS
